TY - JOUR
KW - abuse
KW - Administration, Intranasal
KW - Adolescent
KW - Adult
KW - Analgesics, Opioid
KW - buprenorphine
KW - Buprenorphine, Naloxone Drug Combination/pharmacology
KW - Buprenorphine/pharmacology
KW - Dose-Response Relationship, Drug
KW - Double-Blind Method
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - misuse
KW - Mu agonist
KW - Naloxone/pharmacology
KW - Narcotic Antagonists/pharmacology
KW - narcotics
KW - Opiate Substitution Treatment/methods
KW - Opioid
KW - opioid withdrawal
KW - Opioid-Related Disorders/drug therapy
KW - Oxycodone/pharmacology
KW - Reinforcement (Psychology)
KW - Self Administration
KW - Substance Withdrawal Syndrome/drug therapy
KW - Young Adult
AU - S. L. Walsh
AU - P. A. Nuzzo
AU - S. Babalonis
AU - V. Casselton
AU - M. R. Lofwall
A1 - 
BT - Drug and alcohol dependence
C5 - Opioids & Substance Use
CY - Ireland
DO - 10.1016/j.drugalcdep.2016.03.005
JF - Drug and alcohol dependence
PB - Elsevier Ireland Ltd
PP - Ireland
PY - 2016
SN - 1879-0046; 0376-8716
SP - 190
EP - 198
EP - 
T1 - Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers
T2 - Drug and alcohol dependence
TI - Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers
U1 - Opioids & Substance Use
U2 - 27012435
U3 - 10.1016/j.drugalcdep.2016.03.005
VL - 162
VO - 1879-0046; 0376-8716
Y1 - 2016
ER -